References
- Steinbrook R. Public registration of clinical trials. N Engl. J. Med. 351(4), 315–317 (2004).
- Reicin A. VIoxx Gastrointestinal Outcomes Research (VIGOR). FDA Arthritis Advisory Committee, Merck & Co., PA, USA (2001).
- Murphy KM, Topel R. The Economic Value of Medical Research. University of Chicago, IL, USA (1999).
- Wally T, Haycox A, Boland A. Pharmacoeconomics. Walley T, Haycox A, Boland A (Eds). Churchill Livingstone, London, UK, 127–131 (2004).
- Drummond M, Brown R, Fendrick AM et al. Use of pharmacoeconomics information. Report of the ISPOR task force on use of pharmacoeconomic/health economic information in healthcare decision making. Value Health 6(40), 7–16 (2003).
- Strom B. Pharmacoepidemiology. Third Edition. Strom B (Ed.). John Wiley & Sons Ltd, NJ, USA, 2575–2576 (2000).
- Pharmacoeconomics In Perspective: A Primer On Research, Techniques, and Information. Bonk R (Ed.). Haworth Press, Inc., NY, USA, 15–18 (1999).
- Wechsler J. The high cost of prescription drugs. Pharmaceutical Exec. (11), 12–21 (1991).
- Drummond M, Davies L. Economic analysis alongside clinical trials. Int. J Tech. Assess. Health 7(4), 561–573 (1991).
- Shaya F, Blume S, Mullins D. Prescription drug spending trends for the privately insured in Maryland, 2000–2001. Health Affairs 23 (5), 226–232 (2004).
Websites
- Merck & Co. www.vioxx.com/rofecoxib/vioxx/consumer/ index.jsp (Accessed November 2004)
- National Institute for Clinical Excellence www.nice.org.uk/pdf/TAPpdf (Accessed November 2004)
- International Society for Pharmacoeconomics and Outcomes Research Conference www.ispor.org/workpaper/adpanel/apr.pdf (Accessed November 2004)